Sance Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sance Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $6.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sance Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $6.5M Trade | TransData Nexus

Sance Laboratories Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $6.5M Total Trade · DGFT Verified

Sance Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $6.5M across 4 products in 2 therapeutic categories. Based on 177 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cephalexin ($3.6M), Cefixime ($2.4M), Cefpodoxime ($303.5K).

Sance Laboratories Private Limited — Export Portfolio & Destination Treemap

Sance Laboratories Private Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sance Laboratories Private Limited? — Company Overview & Market Position

Sance Laboratories Private Limited, established on September 20, 2001, is a privately held Indian pharmaceutical company specializing in the manufacturing and export of cephalosporin antibiotic formulations. The company is headquartered in Kottayam, Kerala, India, with its registered office located at VI/51B, Elappunkal Junction, Kozhuvanal P.O., Pala, Kottayam District, Kerala 686573.

The company is classified as a private limited entity under the Corporate Identification Number (CIN) U24231KL2001PTC014957. As of the latest available financial data, Sance Laboratories has an authorized share capital of ₹4,00,00,000 and a paid-up capital of ₹3,95,99,970. In the fiscal year ending March 31, 2025, the company reported a 15.98% increase in total revenue, a 12.85% rise in profit, and a 17.51% growth in net worth, indicating robust financial health.

Sance Laboratories employs a dedicated workforce across various departments, including Quality Assurance, Production, Quality Control, Formulation & Development, Engineering, Finance, and Administration. The company's website, sancepharma.com, provides further insights into its operations and product offerings.

What Does Sance Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cephalexin$3.6M

Product Portfolio — Top 4 by Export Value

Sance Laboratories Private Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cephalexin	Antibiotics	$3.6M	72	1.0%	8
2	Cefixime	Advanced Antibiotics	$2.4M	82	1.4%	15
3	Cefpodoxime	Advanced Antibiotics	$303.5K	18	0.4%	15
4	Ceftazidime	Advanced Antibiotics	$159.5K	5	1.5%	12

Sance Laboratories Private Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $6.5M. The top category is Antibiotics (55.5% of portfolio), followed by Advanced Antibiotics (44.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sance Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sance Laboratories operates a state-of-the-art manufacturing facility located in Kottayam, Kerala, India. The plant is designed to produce a range of cephalosporin antibiotic formulations, including dry powder for injections, tablets, capsules, dry syrups, and sachets. The facility is built over a total land area of 1.5 acres, with a built-up area of 64,000 square feet, and is equipped with modern machinery to ensure high-quality production.

The manufacturing plant has a monthly production capacity of 17 million tablets, 4 million capsules, 0.25 million bottles of dry syrup, and 1.5 million vials of dry powder injections, based on an 8-hour single-shift operation. The facility adheres to stringent quality control measures and complies with international standards, including WHO-GMP, ISO 45001:2018, and ISO 14001:2015 certifications.

3Key Leadership

Sance Laboratories is led by a team of experienced professionals committed to the company's growth and operational excellence. The key executives include:

Manoj Joseph: Managing Director, appointed on September 20, 2001.

Jatin Joseph: Director, appointed on September 20, 2001.

Valsamma Joseph: Director, appointed on September 20, 2001.

Thommas Paul: Whole-Time Director, appointed on August 26, 2021.

These leaders bring a wealth of experience and strategic vision to Sance Laboratories, driving its mission to deliver high-quality pharmaceutical products globally.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sance Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sance Laboratories has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from multiple international regulatory bodies, such as the World Health Organization (WHO), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, and ANVISA of Brazil.

In the United States, Sance Laboratories has registered its manufacturing facility with the Food and Drug Administration (FDA), enabling the export of its products to the U.S. market. The company has also secured approvals from the FDA of Ghana and the Ministry of Health of Sri Lanka, further expanding its reach in these regions.

Sance Laboratories' adherence to Good Manufacturing Practices (GMP) and its commitment to quality have facilitated its entry into these regulated markets, underscoring its capability to meet international standards.

2Emerging Markets

Sance Laboratories has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 50 countries across these regions, including Nigeria, Uganda, Tanzania, Zimbabwe, Kenya, Ghana, Namibia, Sri Lanka, the Philippines, Yemen, and Sudan.

The company's adherence to international standards, such as WHO-GMP, ISO 45001:2018, and ISO 14001:2015 certifications, has facilitated its entry into these markets. Additionally, Sance Laboratories' compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards has enabled it to meet the regulatory requirements of various countries, enhancing its global reach.

Sance Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sance Laboratories has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has also secured approvals from the FDA of Ghana and the Ministry of Health of Sri Lanka, further expanding its reach in these regions.

The company's adherence to Good Manufacturing Practices (GMP) and its commitment to quality have facilitated its entry into these regulated markets, underscoring its capability to meet international standards.

2WHO & EU GMP

Sance Laboratories has obtained certifications from the World Health Organization (WHO) for Good Manufacturing Practices (GMP), ISO 45001:2018, and ISO 14001:2015. These certifications demonstrate the company's commitment to maintaining high-quality manufacturing processes and environmental management systems.

The company's compliance with WHO-GMP standards has facilitated its entry into various international markets, including those in Africa, Latin America, and Southeast Asia. Additionally, Sance Laboratories' adherence to international standards, such as ISO 45001:2018 and ISO 14001:2015, underscores its dedication to quality and environmental management.

CDSCO & Indian Regulatory

Sance Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sance Laboratories operates in the competitive cephalosporin antibiotic market, facing competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's focus on high-quality manufacturing and adherence to international standards positions it favorably in the market.

The company's expansion into over 50 countries, including those in Africa, Latin America, and Southeast Asia, demonstrates its ability to compete effectively in diverse markets.

2Key Differentiators

Sance Laboratories' key differentiators include its specialization in cephalosporin antibiotic formulations, adherence to international quality standards such as WHO-GMP, ISO 45001:2018, and ISO 14001:2015, and its commitment to timely delivery without compromising on quality, safety, and efficacy.

3Strategic Position

Sance Laboratories' current strategic direction focuses

Frequently Asked Questions — Sance Laboratories Private Limited

How many pharmaceutical products does Sance Laboratories Private Limited export from India?

Sance Laboratories Private Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Cephalexin ($3.6M), Cefixime ($2.4M), Cefpodoxime ($303.5K), Ceftazidime ($159.5K). Total export value is $6.5M.

What is Sance Laboratories Private Limited's total pharmaceutical export value?

Sance Laboratories Private Limited's total pharmaceutical export value is $6.5M, based on 177 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sance Laboratories Private Limited cover?

Sance Laboratories Private Limited exports across 2 therapeutic categories. The largest are Antibiotics (55.5%, 1 products), Advanced Antibiotics (44.5%, 3 products).

Get Full Sance Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.